Door is changing the way Houstonians buy their homes. Courtesy photo

Alex Doubet has a plan to shake up Texas real estate. The innovative businessman is taking his disruptive brokerage company statewide. Door, now has imprints in Houston, Dallas, San Antonio, and Austin. And that, he says, is great news for homebuyers and sellers.

"The average homebuyer is paying 6 percent in commission," he says. "And that adds up. Our service, on average, is saving people $12,000 when they buy a house."

When the Dallas-based Door launched in 2015, it shifted the real estate paradigm. Gone was the idea that a homebuyer or seller had to pay a commission to a real estate agent. Gone was the idea that a homebuyer even needed a real estate agent.

"Ninety-five percent of people who are buying a house look online," says Doubet. "They're not necessarily calling a real estate agent and having that agent find houses for them."

The key to Door: Simplicity
So, Doubet took that kind of DIY approach and tweaked it. Every one of his agents is an employee, not an independent contractor. For each sale, the buyer and seller pay a flat, $5,000 fee. Doubet's idea was to be a one-stop shop, where homebuyers could not only find and purchase a home, but also have assistance with mortgage lending and home titles.

"My plan was always to save people money and give them the best experience," he says.

Having now expanded across the Lone Star State, Doubet says that he's ready to share his company's expertise with customers in Houston. Because they're employees, Doubet's agents are focused on providing a high-quality, tailored experience for consumers — not pushing them toward properties that might net a fat commission.

Door has harnessed technology, too, recognizing that most people today transact business in the online world.

"It's something of a brave new world," he says. "But we're using technology to deliver better outcomes for our buyers and sellers."

Buyers will find Door agents are able to work with them to identify properties, schedule home tours, coordinate offers, and assist with the closing. Meanwhile, sellers' agents deliver market analysis, meet the seller at his or her home to do an evaluation, and set up stagings and photo shoots for the listing. Door agents work with their buyers and sellers, as well as with each other, sharing resources and expertise, and making certain that their clients feel like individuals.

Real hot
Clearly, the company is making an impact. Door has a 4.9 star rating on Zillow. And recent news reports from the DFW area indicate the company's processes are hot with millennials, who are known for their own tech savviness and preference for quick, online transactions. Every one of the company's agents is a licensed real estate agent and Door is a member of MLS.

"People are starting to realize there is an alternative to how we buy and sell real estate today," says Doubet. "And we're making sure our clients have a stress-free, easy, cost-efficient experience."

---

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.